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CASE REPORT

Open Access

Papillary thyroid cancer recurrence 43 Years
following Total Thyroidectomy and
radioactive iodine ablation: a case report
Yaw Amoako-Tuffour1*, M. Elise Graham2, Martin Bullock3, Matthew H. Rigby2, Jonathan Trites2, S. Mark Taylor2
and Robert D. Hart2

Abstract
Background: Recurrent papillary thyroid carcinoma (PTC) beyond the first two decades of definitive treatment (i.e.
total thyroidectomy and radioactive iodine ablation) is a rare occurrence.
Case presentation: We present a case of a 71-year old Caucasian female with a distant history of PTC treated with
total thyroidectomy and radioactive iodine ablation who experienced recurrence of her disease 43 years following
initial diagnosis and definitive treatment. She presented with palpable left-sided neck mass and subsequently
underwent a level II, III, neck dissection and adjuvant iodine ablation. This case presents the latest recurrence
in papillary thyroid cancer documented to date in the literature.
Conclusion: This case exemplifies the need for the head and neck surgeon, radiation oncologist, general practitioner
and radiologist to consider new lateral neck mass as late-presenting recurrence of PTC until proven otherwise
regardless of low recurrence rates beyond two decades from treatment and low prognostic risk scores.
Keywords: Papillary thyroid cancer, Thyroidectomy, Radioiodine ablation, Recurrence, Neck dissection, Case report

Background
Papillary thyroid carcinoma (PTC) is the most common
histological type of thyroid-originating malignancy comprising 80% of all thyroid carcinomas [1, 2]. PTC is an
unencapsulated tumor with papillary and follicular structures characterized histologically by overlapping cell nuclei
with ground glass appearance and invaginations of cytoplasm into the nuclei [3]. It differs from the follicular variant in the absence of nuclear changes in the latter. These
tumors are indolent and have a good prognosis, but frequently metastasize to regional lymph nodes in 5.4% to
13% of patients after initial surgery [1]. As a whole, thyroid
cancer generally has a good prognosis with a 5-year
survival rate of 98% [4, 5]. The cornerstone of treatment for PTC patients is total thyroidectomy with postoperative radioactive iodine adjuvant therapy [4, 6]. Recurrence of PTC may be loco-regional or distant, with
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the central compartment typically being the first region
to develop metastatic disease, followed by ipsilateral
lateral neck nodes [7].
In a study spanning 6 decades (1940-1999) of PTC
treated at the Mayo Clinic, recurrence rates followed a
logarithmic trend, meaning that the incremental risk of
recurrence decreased in each subsequent year [2]. The
tumour recurrence rates were 8% at 5 years and 11% at
10 years for the subgroup of 2305 who had localized
disease that was completely excised at the initial surgery. By 25 years, the cumulative recurrence rate
reached 11% and increased to 13% at 40 post-operative
years [2]. More than 80% of recurrences took place during the first decade.
Though most recurrences occur within the first 10
post-operative years, there have been reports of locoregional recurrences a decade or more after this initial
window. Cirocchi reports that local relapses can occur
as late as 20 years after the initial diagnosis and treatment [7, 8]. In another report by Schlumberger et al.,
the authors report a recurrence of differentiated thyroid
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carcinoma 33 years after initial treatment [9]. In a study
of 269 patients which was designed to determine the
length of follow-up needed for post-op thyroid patients,
the authors found that the latest recurrences happened
between 30 and 39 years [10]. The current report presents the case of a loco-regional (lateral neck) recurrence of PTC 43 years after initial treatment. To the
authors’ knowledge, this represents the latest PTC recurrence reported in the literature.

Case presentation
A 71 year old Caucasian female with a remote history of
PTC presented with a 2-month history of palpable leftsided neck mass. Physical examination revealed a nontender mass in the left lateral neck. There were no other
abnormalities identified in a full head and neck examination. There was no palpable mass in the thyroid bed.
Ultrasonography of the neck revealed an absence of normal thyroid tissue, consistent with patient’s history of
distant thyroidectomy, and a solid mass in the left side
of the neck superolateral to the expected location of the
thyroid, in level III. This inhomogeneous mass appeared
vascular and measured 2.8 cm in length by 1.7 cm in
diameter. It was not felt to resemble a normal lymph
node in ultrasonographic features. Nonetheless, from its
appearance and anatomical location, this new mass was
initially suspected to represent a lymph node or a carotid body tumour.
Computed Tomography (CT) ruled out non-nodal
neck pathology, and identified the mass as being consistent with an enlarged lymph node (Figs. 1, 2). Again, this
study revealed no evidence of recurrence in the thyroid
bed, nor other evidence of neoplastic disease.
Two fine needle aspiration biopsies (FNAs) were
performed. The specimens were cellular and consisted of
groups of epithelial cells in flat sheets and papillary-like clusters. The cells showed enlarged nuclei with nuclear grooves
and a few intranuclear inclusions. Immunohistochemistry
on the cell block was positive for TTF-1 (thyroid transcription factor 1), consistent with cells of thyroid origin.
A positron emission tomography (PET) study was performed to rule out distant metastatic disease. Apart from
the known mass in the left neck, the PET study showed no
other Fluorodeoxyglucose (FDG) avid lesions (Fig. 3). Given
these diagnostic findings, the patient was scheduled for a
left lateral neck dissection after obtaining informed consent.
The patient subsequently underwent an uncomplicated left
level II-III neck dissection under general anesthesia. A
timeline of events is presented in Table 1.
Two of the 10 nodes sent for surgical pathology in the
lymphadenectomy specimen returned positive for metastatic papillary thyroid carcinoma of tall cell variant. The
larger of the 2 nodes measured 3.5 cm with focal extranodal extension.

Fig. 1 Computed tomography (transverse plane) revealing
2.8 × 1.7 cm mass in patient’s left lateral neck

The patient recovered well from the operation and
was seen for follow-up three weeks following the left
neck dissection. Given the findings from surgical pathology, it was decided that the patient would benefit from
radioactive iodine ablation and the patient was referred
for adjuvant therapy.

Discussion and conclusions
This patient had a distant history of well-differentiated
papillary thyroid cancer, which was diagnosed and treated
at the age of 28. Her treatment consisted of a total thyroidectomy with post-operative radioactive iodine ablation
therapy. Several scores have been developed to stratify patients’ risk of recurrence. These scores broadly take into
account patient factors, tumour characteristics, and the

Fig. 2 Computed tomography (coronal plane) of the patient’s left
lateral neck mass
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incremental recurrence rate in each subsequent decade.
These studies and a few case reports, however, do highlight that recurrence as late as 39 years can occur. The
case presented in this report details a recurrence 43 years
following treatment.
The extent of postoperative follow-up for patients having received thyroidectomy is informed by the relatively
low rates of recurrence beyond the initial decade and the
surveillance cost of decades-long follow-up. The need to
extend surveillance to these later years is not addressed in
this report and the benefit of doing so is the subject of further study. However, the findings from this case serve to
inform the head and neck surgeon that recurrence has
now been demonstrated to occur into the 5th decade following therapy. The authors recommend that PTC recurrence be considered high on the differential diagnosis for
a new neck mass, regardless of the elapsed time following
initial treatment, until proven otherwise.
Fig. 3 Combined CT/PET capture of fluorodeoxyglucose (FDG) uptake
in left lateral neck mass

selected initial therapy. This patient would have been considered low risk for recurrence by multiple scoring systems: the European Organization for Research and
Treatment of Cancer (EORTC) described by Bryar et al.
[11]; The Age, Grade, Extent and Size (AGES) score developed by Hay [12]; Age, Metastasis, Extent and Size
(AMES) score as described by Cady and Rossi [8]; and the
distant Metastasis, patient Age, Completeness of resection, local Invasion, and tumour Size (MACIS) score [13].
More recent findings of associations with mutations in the
BRAFV600E gene may in the future serve as a better prognosticator of distant PTC recurrence [14–16].
A handful of studies spanning several decades following postoperative thyroid cancer patients demonstrate
that the majority of recurrences occur within the first
decade, and that there is a precipitous drop in the
Table 1 Timeline
1972

Total thyroidectomy, Radioactive iodine ablation

03/2015

Presents to clinic with 2 month history
of neck mass

03/2015

Ultrasound identifying solid mass,
appropriately unable to detect thyroid

04/2015

CT head, neck, and thorax identifying
left-sided level III mass

04/2015

FNA performed on level III mass with
immunohistochemical features consistent
with metastatic papillary thyroid cancer

05/2015

PET/CT Scan performed with FDG (orbits
to the mid-thighs) Local regional recurrence
of papillary thyroid cancer

07/2015

Left selective neck dissection level III
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